Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer

Inclusion Criteria:

For all patients:

* Women over 18 years of age, with histologically confirmed histologic type 1 or type 2 endometrial adenocarcinoma, with FIGO postoperative II or III stage operated between 2011 and 2015, with at least 2 years of follow-up compared to the last course of chemotherapy;
* Recommended surgery such as hysterectomy and bilateral salpingo-oophorectomy, non-mandatory surgical nodal staging;
* Pelvic radiotherapy +/- lumbar-aortic irradiation, optional brachytherapy;
* No recurrence of endometrial cancer at baseline;
* Absence of evolutionary neurological antecedent (multiple sclerosis, neurodegenerative pathology ...);
* Absence of progressive psychiatric pathology (i.e. psychiatric hospitalization, bipolar disorder, schizophrenia, personality disorders ...);
* No opposition to the collection of data;
* Patient deemed fit to answer a written questionnaire.

For the patient in the chemotherapy group - Chemotherapy after surgery that can be performed before or after radiotherapy

Exclusion Criteria:

For all patients:

* Sarcoma or carcinosarcoma;
* Stage FIGO I or IV;
* Macroscopic tumor residue after surgery;
* Recurrence of endometrial cancer or diagnosis of any other cancerous pathology after diagnosis of endometrial cancer (except non-melanotic skin tumors with complete excision), within 5 years;
* drug use;
* Abuse of alcohol.

For the patient in the chemotherapy group

* Chemotherapy before surgery;
* Chemotherapy concomitant with radiotherapy

For the patient in the group without chemotherapy

\- Chemotherapy whether before or after surgery